Michael Rosenblatt.
出版信息
Nat Rev Drug Discov. 2016 Sep 29;15(10):672. doi: 10.1038/nrd.2016.203.
PMID:27681789
Abstract
摘要
相似文献
1
Michael Rosenblatt.
Nat Rev Drug Discov. 2016 Sep 29;15(10):672. doi: 10.1038/nrd.2016.203.
2
Q&A: Bernard Munos.
Nature. 2016 May 12;533(7602):S59. doi: 10.1038/533S59a.
3
Fix the antibiotics pipeline.
Nature. 2011 Apr 7;472(7341):32. doi: 10.1038/472032a.
4
[Open innovation and licensing in the pharmaceutical industry].
Nihon Yakurigaku Zasshi. 2013 Jul;142(1):28-31. doi: 10.1254/fpj.142.28.
5
[Open innovation for Japanese pharmaceutical companies].
Nihon Yakurigaku Zasshi. 2013 Oct;142(4):184-9. doi: 10.1254/fpj.142.184.
6
The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes.
Drug Discov Today. 2015 Aug;20(8):917-9. doi: 10.1016/j.drudis.2015.06.005. Epub 2015 Jun 19.
7
Ian Tomlinson.
Nat Rev Drug Discov. 2016 Mar;15(3):154. doi: 10.1038/nrd.2016.22. Epub 2016 Feb 19.
8
Open innovation: share or die..
Drug Discov Today. 2009 Nov;14(21-22):1003-5. doi: 10.1016/j.drudis.2009.09.001. Epub 2009 Sep 22.
9
Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases.
Nat Rev Drug Discov. 2015 Jun;14(6):442-4. doi: 10.1038/nrd4001-c1.
10
[Open innovation: public-private partnerships in pharmaceutical R&D].
Nihon Yakurigaku Zasshi. 2013 Jul;142(1):32-8. doi: 10.1254/fpj.142.32.
Zotero 插件